# LL-37 (cathelicidin)

Source: https://aminodesk.com/library/ll-37
Publisher: Amino Desk
Updated: 2026-11-17
Clinical review: pending

LL-37 is an antimicrobial peptide the body makes itself, part of the skin's first line of defense. It has been tested in people only as a topical treatment for leg ulcers, with mixed results. It is sold online as an injection, which has never been studied.

- **Legal lane:** no approved product; FDA compounding review due by February 2027
- **Evidence grade:** C
- **Studied form:** applied to wounds
- **Sold form:** injectable powder

## What it is

LL-37 is the only human cathelicidin, a family of peptides that kill bacteria and help coordinate wound repair. Chronic wounds tend to have low levels of it, which is the reasoning behind applying it directly.

## What the evidence shows

- A 2014 trial in 34 people with hard-to-heal venous leg ulcers found faster healing with the two lower strengths applied twice a week, and no benefit at the highest strength.
- A larger 2021 trial in 148 people found no significant improvement in healing over placebo across the whole group.

Both trials put LL-37 on the wound. No human trial has tested it as an injection, for immune support, or for anything else it is sold for.

## Dosing

**No dose established.** The only human dosing is topical concentrations applied to ulcers in clinical trials. Nothing in that work tells you what an injected dose would do.

## Legal status

In April 2026 the FDA took LL-37 off its list of substances flagged as significant safety risks for compounding. That is not permission to compound it. An FDA advisory committee is scheduled to review it, with GHK-Cu, dihexa, Melanotan II and PEG-MGF, before the end of February 2027.

## Common questions

### Has LL-37 been tested in people?

Only as a topical treatment for leg ulcers, with mixed results. A 2014 trial in 34 people found faster healing at lower strengths. A larger 2021 trial in 148 people found no significant improvement over placebo.

### Can pharmacies compound LL-37?

Not currently. Its April 2026 removal from the FDA's safety-risk list is not permission to compound it. An advisory committee is scheduled to review it before the end of February 2027.

### Is there a dose for injected LL-37?

No. No human trial has tested LL-37 as an injection.

Added in the latest update. These answers summarize the sections above; sources are listed below.

## Sources

- [Grönberg et al. 2014: LL-37 for venous leg ulcers, randomized trial (PubMed)](https://pubmed.ncbi.nlm.nih.gov/25041740/)
- [HEAL LL-37, 2021: Phase 2b trial in 148 patients (PubMed)](https://pubmed.ncbi.nlm.nih.gov/34687253/)
- [FDA: upcoming Pharmacy Compounding Advisory Committee meeting](https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/meeting-pharmacy-compounding-advisory-committee)

---
Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL.
